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Summary
The Muckle-Wells syndrome (MWS) is a hereditary
inflammatory disorder characterized by acute febrile
inflammatory episodes comprising abdominal pain, ar-
thritis, and urticaria. Progressive nerve deafness develops
subsequently, and, after several years, the disease is com-
plicated by multiorgan AA-type amyloidosis (i.e., amy-
loidosis derived from the inflammatory serum amy-
loid–associated protein) (MIM 191900) with renal
involvement and end-stage renal failure. The mode of
inheritance is autosomal dominant, but some sporadic
cases have also been described. No specific laboratory
findings have been reported. The genetic basis of MWS
is unknown. Using a genomewide search strategy in
three families, we identified the locus responsible for
MWS, at chromosome 1q44. Our results indicate that
the gene is located within a 13.9-cM region between
markers D1S2811 and D1S2882, with a maximum two-
point LOD score of 4.66 (recombination fraction .00)
at D1S2836 when full penetrance is assumed. Further
identification of the specific gene that is responsible for
MWS will therefore provide the first biological element
for characterizingMWS, other than doing so on the basis
of its variable clinical expression.
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Introduction
The Muckle-Wells syndrome (MWS [MIM 191900])
was first described, in 1962, as a rare hereditary disorder
with an autosomal dominant mode of inheritance (Muc-
kle and Wells 1962). Since that time, the majority of
published studies have focused on kindreds from north-
ern Europe. The disease is characterized by acute febrile
inflammatory episodes (denoted as “aguey bouts” in
Derbyshire, United Kingdom, the region where the first
families with MWS were described). The inflammatory
episodes, which commonly manifest in childhood, in-
clude abdominal pain, joint inflammation, myalgia, ur-
ticaria, and conjunctivitis. These episodes last 24–48 h.
Later in the course of the disease, nerve deafness occurs.
After several years, the inflammatory condition is com-
plicated by the development of amyloidosis of the AA
type (i.e., amyloidosis derived from the inflammatory
serum amyloid–associated protein), which can involve
most tissues and organs but which especially involves
the kidney (Muckle and Wells 1962; Muckle 1979;
Linke et al. 1983; Messier et al. 1988). Twenty-six per-
cent of patients have renal amyloidosis that is revealed
by proteinuria, leads to nephrotic syndrome, and de-
velops to end-stage renal failure, which, before the era
of maintenance hemodialysis, was fatal (Muckle and
Wells 1962; Lagrue et al. 1972; Prost et al. 1976; Muckle
1979; Watts et al. 1994). AA amyloidosis is not required
for the diagnosis of MWS, since (1) this complication is
delayed in the course of the disease, (2) it can be clinically
latent (Messier et al. 1988), and (3) it apparently does
not occur in every kindred.
At the time when acute clinical episodes occur, lab-
oratory testing may show an acute-phase response with
a high erythrocyte sedimentation rate, high leukocyte
blood counts, and hypergammaglobulinemia. Although
a circadian increase in interleukin-6 blood levels has re-
cently been documented during urticarial flares in a pa-
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tient with MWS, the cause and the pathogenesis of the
disease remain unknown (Gerbig et al. 1998). No treat-
ment has been proved to be beneficial for MWS, al-
though our own experience with family 1 suggests that
colchicine exerts a favorable effect on the intensity and
repetition of aguey bouts (Messier et al. 1988). The rar-
ity of MWS and the lack of long-term observation leave
unresolved the issue of prevention of amyloidosis with
protracted colchicine treatment.
The periodic occurrence of inflammatory crises and
the potential threat of amyloidosis are reminiscent of
characteristics of other hereditary periodic inflammatory
diseases (Grateau et al. 1999). These inflammatory dis-
eases are familial Mediterranean fever (FMF); the syn-
drome of hyperimmunoglobulinemia D and periodic fe-
ver (HIDS) (Drenth et al. 1994), both of which have an
autosomal recessive mode of inheritance; and the group
of autosomal dominant recurrent fevers (ADRF) (Mulley
et al. 1998), including familial Hibernian fever (FHF),
which is the best-characterized fever within this group
(McDermott et al. 1997, 1998).
The gene responsible for FMF, which maps to chro-
mosome 16p13, has been identified; it encodes a putative
leukocyte transcriptional factor known as “marenostrin/
pyrin” (The French FMF Consortium 1997; The Inter-
national FMF Consortium 1997). More recently, mu-
tations in the mevalonate kinase gene, which is located
at 12q24, have been shown to cause HIDS (Drenth et
al. 1999, Houten et al. 1999), whereas in families with
FHF and in some families with ADRF the disease is
caused by missense mutations in the tumor-necrosis-fac-
tor (TNF) receptor 1 (TNFR1) gene, located at chro-
mosome 12p13 (McDermott et al. 1999). McDermott
has proposed the term “TRAPS” (TNF recep-
tor–associated periodic syndromes) to define this disease
group.
In an effort to localize the MWS gene, we undertook
a genomewide scan, using 276 microsatellite markers,
in one English family and in two French families. This
led to mapping the disease locus to the long arm of
chromosome 1 at 1q44.
Patients, Material, and Methods
Patients
This project was approved by the ethics committees
of Cochin Hospital, Paris, and Norfolk and Norwich
Hospital, Norwich, United Kingdom. Three families
comprising a total of 35 individuals, including 18 af-
fected individuals, were studied. Each participant was
interviewed and examined and provided written in-
formed consent. Studies of some members of these fam-
ilies have been published elsewhere (Lagrue et al. 1972;
Prost et al. 1976; Messier et al. 1988; Watts et al. 1994),
and the pedigree structure of those individuals partici-
pating in this study is shown in figure 1. Characteristic
signs of the disease, such as inflammatory crises with
urticaria, conjunctivitis, arthralgias, and nerve deafness,
were present in all three families. However, amyloidosis
of the AA type was observed only in family 1 (Lagrue
et al. 1972; Messier et al. 1988). Intermittent oligoar-
ticular synovitis, which affected the large joints and was
unresponsive to treatment with colchicine, was reported
in family 3 (Watts et al. 1994).
Genotyping
Peripheral blood was obtained from all individuals,
and DNA was extracted, by means of the standard phe-
nol/chloroform method, from a lymphocyte pellet. The
genomewide screening was performed with the Associ-
ation Franc¸aise contre les Myopathies/Ge´ne´thon panel
of 276 fluorescent microsatellite markers at a resolution
of 12–14 cM. The PCR products for each template were
appropriately pooled, and an aliquot was loaded onto
a 5% standard denaturating polyacrylamide gel and was
run in an Applied Biosystems (ABI) 373A automated
DNA sequencer. Allele sizes were determined on the ba-
sis of an internal size standard in each lane (500 Tamra;
PE Biosystems ABI), and results were processed by
GeneScan 2.1.1. (ABI) software. After allele assignment
was done with the use of Genotyper 1.1.1. (ABI) soft-
ware, each allelic profile was verified by two individuals,
and the genotypes were checked for Mendelian segre-
gation, by use of the Marksyn (Ge´ne´thon) software.
Linkage Analysis
Statistical analyses were performed on the basis of an
autosomal dominant disease with full penetrance. The
frequency of the abnormal allele was set at .0001, in
view of the rarity of the disorder. The feasibility of the
linkage study was explored by use of SLINK (Ott 1989).
Pairwise LOD scores were calculated, with isofrequen-
cies of the marker alleles being assumed, by use of the
MLINK subroutine of the FASTLINK 4.0 package
(which also contains ILINK and LINKMAP) (Cot-
tingham et al. 1993). Values for the maximum LOD
score (Zmax) were calculated by the ILINK program. The
recombination frequency was assumed to be equal for
both sexes. Multipoint LOD scores were calculated by
use of the LINKMAP subroutine. Haplotypes, which
were constructed and assigned in such a way as to min-
imize the number of crossovers in each family, were an-
alyzed to determine the minimal candidate region for
the location of MWS. Homogeneity was tested by means
of the HOMOG program (Ott 1991).
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Figure 1 Pedigree of the three families with haplotype analysis in the region of linkage on chromosome 1. Affected individuals are shown
as blackened circles (females) or blackened squares (males). Deceased individuals are denoted by diagonal slashes.
Results
Segregation of the disease in the families suggests the
presence of a single disease gene with an autosomal dom-
inant mode of inheritance and very high penetrance. Be-
cause MWS is reminiscent of other hereditary periodic
inflammatory diseases, we first investigated linkage anal-
yses at loci 16p13 (for FMF), 12q24 (for HIDS), and
12p13 (for FHF). Two-point LOD scores between the
disease and markers (surrounding 10–18-cM regions)
were strongly negative in the three families (data not
shown), and no single haplotypes were shared among
affected individuals. This finding excluded the genomic
regions of FMF, HIDS, and FHF as being responsible
for MWS. SLINK simulation showed that linkage de-
tection by means of a genomewide search was feasible
with these three families, and a semiautomated ge-
nomewide search for linkage was initiated with 276 fluo-
rescent microsatellite markers at a resolution of 12–14
cM. Under the assumption of full penetrance, two-point
LOD scores showed linkage to the subterminal region
of the long arm of chromosome 1. Initially, a suggestive
LOD score of 2.76 (recombination fraction [v] = .05)
was obtained for the marker at locus D1S2682, and all
the Ge´ne´thon-map microsatellite markers in the region
were typed (to an average density of five markers per
23 cM). Linkage was obtained with a Zmax of 4.66 (v =
.00) at marker D1S2836 (table 1). The LOD scores did
not change when they were calculated with penetrance
values of .95, .90, and .85 (data not shown).
Haplotypes were constructed by parsimony (fig. 1).
Several recombinants that defined the limits of the MWS
region were detected. Analysis of individual 16 in family
2 showed that the centromeric limit of the MWS interval
is located between markers D1S2811 and D1S2836.
This limit could not be defined more precisely, since the
affected mother (individual 13) was homozygous for
marker D1S423. The recombinant event in family 1 (in-
dividual 9) suggested that the telomeric limit would be
located between markers D1S2836 and D1S2682, but
this could not be confirmed, since the haplotype of the
affected father (individual 1) is unknown. No common
haplotype was apparent in these three families. The
HOMOG program detected no evidence to support ge-
netic heterogeneity. A maximum log likelihood of 10.73
was obtained for a = 1, at marker D1S2836, where a
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Table 1
Two-Point Linkage Analysis Data for the MWS Gene and Markers Spanning a Sex-
Averaged Interval of 20 cM at Chromosome 1q44
LOD SCORE AT v =
MARKER .00 .01 .05 .1 .2 .3 .4 Zmax v
D1S235  2.69 –.79 .15 .23 .25 .15 .26 .258
D1S2785  6.62 2.67 1.18 .04 .29 .26 .31 .336
D1S304  1.66 .36 .1 .37 .36 .22 .43 .236
D1S2842  1.05 .82 1.40 1.53 1.17 .59 1.59 .167
D1S2811  1.00 .32 .78 .98 .80 .41 .99 .190
D1S423 1.43 1.43 1.33 1.19 .86 .61 .19 1.43 0
D1S2836 4.66 4.59 4.30 3.89 2.96 1.93 .86 4.66 0
D1S2682  2.38 2.76 2.64 2.5 1.29 .61 2.77 .053
Table 2
HOMOG Analysis
Hypothesisa df x2 Likelihood Ratio
H2 vs. H1 1 .000 1.0000
H1 vs. H0 1 21.460 4.571x104
H2 vs. H0 2 21.460 4.571x104
a H0 = no linkage; H1 = linkage with homogeneity; H2 = linkage
with heterogeneity.
is the proportion of families with linkage to chromosome
1q (table 2). Therefore, the minimal region of linkage is
defined by a 13.9-cM critical interval, extending from
marker D1S2811 to marker D1S2682, that must contain
the MWS gene. Multipoint linkage analysis (fig. 2) con-
firmed the localization.
Discussion
The results of the present study have identified, in
three families, a major-gene locus for MWS, at chro-
mosome 1q44. We first excluded linkage to the loci for
FMF, HIDS, and ADRF, which are located at 16p13.3,
12q24, and 12p13, respectively. A genomewide search
strategy was then adopted, and we found a suggestive
LOD score of 2.76 (v = .05) at locus D1S2682. In this
region, we tested all available markers from the Ge´ne´-
thon map and obtained a Zmax of 4.66 (v = .00) at marker
D1S2836. The genomewide scan did not support linkage
to any other site. Intrafamilial recombination analyses
placed the MWS locus within a 13.9-cM interval be-
tween markers D1S2811 and D1S2682. This localiza-
tion was confirmed by a multipoint linkage analysis,
whereas the results obtained with the HOMOG program
were consistent with genetic homogeneity in the three
families. However, because of the small number of fam-
ilies in this study, genetic heterogeneity cannot be defin-
itively excluded for MWS.
In these three families, MWS appeared to segregate
as an autosomal dominant trait, with complete pene-
trance and variable expression being consistent with cur-
rent data on MWS. In particular, variable expression was
observed in family 1, in which individual 5, a 70-year-
old woman, has arthralgia only, although several of her
children (who refused to participate in the study) exhibit
a complete clinical phenotype. Sporadic cases of MWS
have also been reported. It is unclear whether these spo-
radic cases are, in fact, familial cases in kindreds with
incomplete penetrance, new mutations, variable clinical
expression, and either underdiagnosis of mild forms of
the disease or misdiagnosis of such close entities as the
chronic infantile neurological cutaneous articular syn-
drome (Prieur et al. 1987). Given the lack of specific
laboratory markers to substantiate the diagnosis of
MWS, mild or atypical forms of the disease may be
underdiagnosed. When genetically linked DNA markers
become available, this should no longer be the case, and
an accurate tool for diagnosis of MWS, even in the ab-
sence of explicit symptomatology, will then be provided.
Family 3 is English, and families 1 and 2 are, respec-
tively, from the western and northern regions of France.
Historically, both of these regions of France were oc-
cupied by the English armies for a long period during
the Hundred Years War. Virtually all members of family
1 are fair haired and blue eyed. We traced the origins
of this family back to the year 1600 and to a small town
near Beauvais, France, where a common (village green)
is still named “Le Clos aux Anglais” (Englishmen’s
Field). Therefore, given the rarity of MWS, it may be
hypothesized that there is a founder effect. Haplotype
analysis of the three families did not show any common
region in the disease-bearing chromosomes. This finding
suggests that the mutation is different in each family.
However, we cannot exclude an ancient founder effect,
which would not be detected with markers spaced only
a few centimorgans from each other. Only characteri-
zation of the mutation or analysis of the polymorphisms
within the gene would address this hypothesis.
In the families that we studied, some degree of clinical
variability was observed with regard to urticaria, deaf-
ness, and joint involvement, which suggests the existence
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Figure 2 Multipoint linkage analysis between MWS and selected
markers on chromosome 1q. D1S2811 was arbitrarily assigned po-
sition 0, and the order and genetic distances of the maker loci were
determined by the use of the Ge´ne´thon genetic map (Dib et al. 1996).
of modulating genes. Amyloidosis, which is a main com-
plication of MWS, has been observed only in family 1
(Messier et al. 1988). This is not surprising, since, for
the reasons given above, AA amyloidosis is not an oblig-
atory finding in MWS. This is also the case for such
other hereditary inflammatory syndromes as FMF and
ADRF, in which amyloidosis affects only some individ-
uals in a given family and never even develops in some
families. Amyloidosis is also known to occur, in some
individuals, as a complication of such nonhereditary
chronic inflammatory disorders as rheumatoid arthritis.
As in the aforementioned inflammatory disorders, the
occurrence of amyloidosis in MWS probably depends
on additional genetic and environmental factors.
MWS can be viewed as a composite syndrome ger-
mane to such recurrent inflammatory syndromes as
FMF, HIDS, and ADRF, as well as to familial urticaria
and hereditary deafness. Many cytokine-network de-
rangements have been described in FMF and HIDS.
Some of the main cytokine or cytokine-receptor genes
have been considered as candidate genes for these dis-
eases. However, since the genes responsible for both of
these syndromes do not encode this class of molecules,
cytokine dysregulation appears to be a secondary event
in these inflammatory diseases. Conversely, it has been
shown that a gene responsible for at least one form of
ADRF encodes TNFR1 (McDermott et al. 1999); the
mutations of this gene lead to unmatched binding of
soluble forms of TNFR1 to TNF. An early study of cir-
culating cytokines and cytokine receptors did not find
any significant modifications in either the soluble form
or the TNFR1 concentration during the inflammatory
episode (Mc Dermott and Powell 1997). However,
McDermott et al. (1999) recently reported that p55 lev-
els were significantly depressed in carriers of the TNFR1
mutations, compared with such levels in normal indi-
viduals, and that, although they do rise during an in-
flammatory episode, the increase is much less than that
seen during an inflammatory response in individuals
without such mutations. Thus, although dysregulation
of the circadian rhythm of interleukin-6 has recently
been shown in one family with MWS (Gerbig et al.
1998), one must be cautious in approaching the cause
of the disease via cytokines.
The MWS localization that we have characterized also
constitutes a candidate region for such diverse famil-
ial forms of urticaria as cold hypersensitivity (MIM
120100), aquagenic urticaria (MIM 191850), mast-cell
disease (MIM 154800), dermodistortive urticaria (MIM
125630), and localized heat urticaria (MIM 191950),
for which none of the responsible genes has yet been
cloned or even localized.
The most intriguing clinical feature of MWS is nerve
deafness, which best distinguishes MWS from other in-
flammatory disorders. To the best of our knowledge, in
only one case (Muckle and Wells 1962) was the inner
ear of a patient with MWS studied at autopsy. Dissection
excluded inner-ear amyloidosis, and deafness was at-
tributed to absence of both Corti’s organ and the ves-
tibular sensory epithelium, in addition to cochlear nerve
atrophy and basilar membrane ossification. However, we
are not aware of any data regarding a gene that underlies
syndromic or nonsyndromic deafness and that would be
located within the interval containing the MWS gene
(Kalatzis and Petit 1998). In addition, by use of the
GeneMap’98 database, no obvious candidate gene was
identified in the disease interval
Our localization of the MWS gene on the long arm
of chromosome 1 opens the way for important devel-
opments. First, mapping of the gene will provide a bi-
ological marker in a disease with various clinical ex-
pressions. Second, cloning—presumably, positional
cloning—of the gene may lead to elucidation of the links
between urticaria, the inflammatory response leading to
AA amyloidosis, and deafness.
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